virus (MHV68) infection in interferon gamma receptor (IFNγ) knockout mice and mouse adapted Zaire Ebola infection with marked reduction in vasculitis, pulmonary hemorrhage, and congestion. Methods: We have assessed
crucial in managing and reducing the pandemic threats of bird flu, swine flu, SARS, Ebola, etc. and alleviating their negative impacts on the society and danger to mankind
herpes virus (MHV68) in interferon gamma receptor (IFNgR) knockout mice. and mouse adapted Zaire Ebola infection with associated reduced pulmonary hemorrhage, and congestion Serp-1 has also been tested
especially against those with multiple strains or serotypes. The hemorrhagic fevers caused by the Ebola and Marburg viruses are among the most deadly diseases to affect humans, and are fatal
shock. VHF?s are caused by four families of virus: arenavirus (Lassa virus), filovirus (Ebola virus), bunyavirus (Rift Valley fever) and flavivirus (Dengue virus). Both anti-virals and vaccines have
pathogens. Many of these high-consequence pathogens, including Venezuelan equine encephalitis virus (VEEV), Ebola virus (EBOV), Marburg virus (MARV), and Lassa virus (LASV), are classified as biothreat agents
Ebola and Marburg viruses are emerging/re-emerging zoonotic pathogens that cause severe viral hemorrhagic fever with case-fatality rates up to 90% in humans. Over the last three decades
Ebolavirus is a member of the family Filoviridae and the cause of Ebola hemorrhagic fever (EHF). Since it was fi rst recognized in 1976, more than 18 outbreaks have occurred
also exhibits activities against two isolates of human immunodeficiency virus (HIV) and the Zaire Ebola (ZEBOV) strain expressing green fluorescent protein (GFP). The therapeutic indices for antiviral activity against
results are also seen from other neuro-tropic RNA viral infections including HTLV-1, Ebola, RVFV and Zika infection which will be discussed. Therefore, targeting these particles
children and adults are being immunised globally. Research on new vaccines for HIV, Ebola, Zika, Dengue, Universal Influenza vaccines and yellow fever are in the pipeline. New manufacturing technologies
some glycoprotein (GP) specific monoclonal antibodies (mAbs) can protect experimental animals against the filovirus Ebola virus (EBOV). Multiple mAbs have been isolated previously from blood samples of human survivors
cell repertoire of an HIV-1 slow progressor and high-affinity neutralizing antibodies targeting Ebola virus (EBOV) glycoprotein from a vaccinated donor. Additional studies related to Zika virus
emerging pathogens originated from animals after having crossed the species barrier (e.g., Ebola) and re-appearance of old diseases like pertussis, measles and known limitations of drugs underline need
Increasing threat of emerging infectious disease like, Ebola, Marburg, different strain of Influenza and other viral and bacterial agents with no active prevention available needs critical consideration to develop
vectors were selected to generate vaccines for different pathogens including malaria, hepatitis C virus, Ebola and RSV. Solid preclinical data on the safety, immunogenicity and efficacy of these ChAd based
original ecological niche to new lands and continents. While the former viruses such as Ebola and SARS/MERS-CoV are completely new for humans, many arboviruses represent paradigmatic examples
health of millions of people around the world with recent outbreaks such as Ebola and Zika claiming thousands of lives and costing billions of dollars. Vaccines contributing to outbreak prevention
such as HIV-1 and infl uenza stimulate strain-specifi c immunity, dengue and ebola stimulate disease-enhancing immunity, and most bacterial pathogens stimulate immune responses lacking anti-bacterial activities
strains of viruses reduces its success. Diseases like AIDS and new viruses such as Ebola still await suitable vaccines. Here comes the role of cure – treatment process. For chronic diseases
China NMEP, as well as stricter measurements carried out at PoE when MERS, Ebola, Zika and Yellow fever spread globally, partly due to more sensitive detect methods used
variants of COVID-19, Influenza and emerging viral infections as was experienced with recent Ebola outbreaks in western Africa or the expanding spread of Zika virus. Our group of collaborators
For authors and organisers
Publish, present and keep up with your field
Find the right journal for your paper and submit your manuscript.